A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model

Sachin Gupta, James M. Termini, Yaelis Rivas, Miguel Otero, Francesca N. Raffa, Vikas Bhat, Amjad Farooq, Geoffrey Stone

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Vaccination with tumor-associated antigens can induce cancer-specific CD8+ T cells. A recent improvement has been the targeting of antigen to dendritic cells (DC) using antibodies that bind DC surface molecules. This study explored the use of multi-trimers of CD40L to target the gp100 melanoma tumor antigen to DC. The spontaneously-multimerizing gene Surfactant Protein D (SPD) was used to fuse gp100 tumor antigen and CD40L, creating the recombinant protein SPD-gp100-CD40L. This "third generation" DC-targeting vaccine was designed to both target antigen to DC and optimally activate dendritic cells by aggregating CD40 trimers on the DC membrane surface. SPD-gp100-CD40L expressed as a 110. kDa protein. Analytical light scattering analysis gave elution data corresponding to 4-trimer and multi-trimer SPD-gp100-CD40L oligomers. The protein was biologically active on dendritic cells and induced CD40-mediated NF-κB signaling. DNA vaccination with SPD-gp100-CD40L plasmid, together with plasmids encoding IL-12p70 and GM-CSF, significantly enhanced survival and inhibited tumor growth in a B16-F10 melanoma model. Expression of gp100 and SPD-CD40L as separate molecules did not enhance survival, highlighting the requirement to encode gp100 within SPD-CD40L for optimal vaccine activity. These data support a model where DNA vaccination with SPD-gp100-CD40L targets gp100 to DC in situ, induces activation of these DC, and generates a protective anti-tumor response when given in combination with IL-12p70 and GM-CSF plasmids.

Original languageEnglish (US)
Article number16768
Pages (from-to)4798-4806
Number of pages9
JournalVaccine
Volume33
Issue number38
DOIs
StatePublished - Sep 11 2015

Fingerprint

CD40 Ligand
Experimental Melanomas
DNA Vaccines
Pulmonary Surfactant-Associated Protein D
Neoplasm Antigens
recombinant vaccines
dendritic cells
melanoma
Dendritic Cells
Cell Survival
surfactants
antigens
neoplasms
proteins
plasmids
Vaccination
Plasmids
vaccination
Granulocyte-Macrophage Colony-Stimulating Factor
gp100 Melanoma Antigen

Keywords

  • B16-F10 melanoma
  • Cancer vaccine
  • CD40L
  • Dendritic cell
  • DNA vaccine
  • Surfactant protein D

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. / Gupta, Sachin; Termini, James M.; Rivas, Yaelis; Otero, Miguel; Raffa, Francesca N.; Bhat, Vikas; Farooq, Amjad; Stone, Geoffrey.

In: Vaccine, Vol. 33, No. 38, 16768, 11.09.2015, p. 4798-4806.

Research output: Contribution to journalArticle

Gupta, Sachin ; Termini, James M. ; Rivas, Yaelis ; Otero, Miguel ; Raffa, Francesca N. ; Bhat, Vikas ; Farooq, Amjad ; Stone, Geoffrey. / A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. In: Vaccine. 2015 ; Vol. 33, No. 38. pp. 4798-4806.
@article{c53953d4cc5f44339629ce0028b587ee,
title = "A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model",
abstract = "Vaccination with tumor-associated antigens can induce cancer-specific CD8+ T cells. A recent improvement has been the targeting of antigen to dendritic cells (DC) using antibodies that bind DC surface molecules. This study explored the use of multi-trimers of CD40L to target the gp100 melanoma tumor antigen to DC. The spontaneously-multimerizing gene Surfactant Protein D (SPD) was used to fuse gp100 tumor antigen and CD40L, creating the recombinant protein SPD-gp100-CD40L. This {"}third generation{"} DC-targeting vaccine was designed to both target antigen to DC and optimally activate dendritic cells by aggregating CD40 trimers on the DC membrane surface. SPD-gp100-CD40L expressed as a 110. kDa protein. Analytical light scattering analysis gave elution data corresponding to 4-trimer and multi-trimer SPD-gp100-CD40L oligomers. The protein was biologically active on dendritic cells and induced CD40-mediated NF-κB signaling. DNA vaccination with SPD-gp100-CD40L plasmid, together with plasmids encoding IL-12p70 and GM-CSF, significantly enhanced survival and inhibited tumor growth in a B16-F10 melanoma model. Expression of gp100 and SPD-CD40L as separate molecules did not enhance survival, highlighting the requirement to encode gp100 within SPD-CD40L for optimal vaccine activity. These data support a model where DNA vaccination with SPD-gp100-CD40L targets gp100 to DC in situ, induces activation of these DC, and generates a protective anti-tumor response when given in combination with IL-12p70 and GM-CSF plasmids.",
keywords = "B16-F10 melanoma, Cancer vaccine, CD40L, Dendritic cell, DNA vaccine, Surfactant protein D",
author = "Sachin Gupta and Termini, {James M.} and Yaelis Rivas and Miguel Otero and Raffa, {Francesca N.} and Vikas Bhat and Amjad Farooq and Geoffrey Stone",
year = "2015",
month = "9",
day = "11",
doi = "10.1016/j.vaccine.2015.07.081",
language = "English (US)",
volume = "33",
pages = "4798--4806",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "38",

}

TY - JOUR

T1 - A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model

AU - Gupta, Sachin

AU - Termini, James M.

AU - Rivas, Yaelis

AU - Otero, Miguel

AU - Raffa, Francesca N.

AU - Bhat, Vikas

AU - Farooq, Amjad

AU - Stone, Geoffrey

PY - 2015/9/11

Y1 - 2015/9/11

N2 - Vaccination with tumor-associated antigens can induce cancer-specific CD8+ T cells. A recent improvement has been the targeting of antigen to dendritic cells (DC) using antibodies that bind DC surface molecules. This study explored the use of multi-trimers of CD40L to target the gp100 melanoma tumor antigen to DC. The spontaneously-multimerizing gene Surfactant Protein D (SPD) was used to fuse gp100 tumor antigen and CD40L, creating the recombinant protein SPD-gp100-CD40L. This "third generation" DC-targeting vaccine was designed to both target antigen to DC and optimally activate dendritic cells by aggregating CD40 trimers on the DC membrane surface. SPD-gp100-CD40L expressed as a 110. kDa protein. Analytical light scattering analysis gave elution data corresponding to 4-trimer and multi-trimer SPD-gp100-CD40L oligomers. The protein was biologically active on dendritic cells and induced CD40-mediated NF-κB signaling. DNA vaccination with SPD-gp100-CD40L plasmid, together with plasmids encoding IL-12p70 and GM-CSF, significantly enhanced survival and inhibited tumor growth in a B16-F10 melanoma model. Expression of gp100 and SPD-CD40L as separate molecules did not enhance survival, highlighting the requirement to encode gp100 within SPD-CD40L for optimal vaccine activity. These data support a model where DNA vaccination with SPD-gp100-CD40L targets gp100 to DC in situ, induces activation of these DC, and generates a protective anti-tumor response when given in combination with IL-12p70 and GM-CSF plasmids.

AB - Vaccination with tumor-associated antigens can induce cancer-specific CD8+ T cells. A recent improvement has been the targeting of antigen to dendritic cells (DC) using antibodies that bind DC surface molecules. This study explored the use of multi-trimers of CD40L to target the gp100 melanoma tumor antigen to DC. The spontaneously-multimerizing gene Surfactant Protein D (SPD) was used to fuse gp100 tumor antigen and CD40L, creating the recombinant protein SPD-gp100-CD40L. This "third generation" DC-targeting vaccine was designed to both target antigen to DC and optimally activate dendritic cells by aggregating CD40 trimers on the DC membrane surface. SPD-gp100-CD40L expressed as a 110. kDa protein. Analytical light scattering analysis gave elution data corresponding to 4-trimer and multi-trimer SPD-gp100-CD40L oligomers. The protein was biologically active on dendritic cells and induced CD40-mediated NF-κB signaling. DNA vaccination with SPD-gp100-CD40L plasmid, together with plasmids encoding IL-12p70 and GM-CSF, significantly enhanced survival and inhibited tumor growth in a B16-F10 melanoma model. Expression of gp100 and SPD-CD40L as separate molecules did not enhance survival, highlighting the requirement to encode gp100 within SPD-CD40L for optimal vaccine activity. These data support a model where DNA vaccination with SPD-gp100-CD40L targets gp100 to DC in situ, induces activation of these DC, and generates a protective anti-tumor response when given in combination with IL-12p70 and GM-CSF plasmids.

KW - B16-F10 melanoma

KW - Cancer vaccine

KW - CD40L

KW - Dendritic cell

KW - DNA vaccine

KW - Surfactant protein D

UR - http://www.scopus.com/inward/record.url?scp=84940718759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940718759&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.07.081

DO - 10.1016/j.vaccine.2015.07.081

M3 - Article

C2 - 26241951

AN - SCOPUS:84940718759

VL - 33

SP - 4798

EP - 4806

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 38

M1 - 16768

ER -